Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
631 articles
A Lancet commentary reexamines the true preventive benefit of colonoscopy screening, challenging assumptions about how we calculate cancer risk reduction.
A completed phase I trial tests regorafenib plus dual checkpoint inhibitors in 39 patients with hard-to-treat metastatic colorectal cancer.
A completed Phase 2 trial tests nivolumab plus ipilimumab in CDK12-mutant metastatic prostate and solid tumors across 56 patients.
A novel immune-evasion mechanism in triple-negative breast cancer reveals how cancer stem cells suppress anti-tumor immunity via extracellular vesicles.
A triple immunotherapy unlocks anti-tumor CD4+ T cells — not CD8+ — to clear pancreatic tumors in mice, reshaping the immunotherapy playbook.
High-level randomized evidence quantifies genitourinary toxicity burden over time following prostate radiotherapy, with direct implications for treatment decisions.
Ficerafusp alfa plus pembrolizumab shows striking results in HPV-negative head and neck cancer, a notoriously difficult-to-treat population.
Researchers identify four LSC subtypes that predict venetoclax resistance and reveal matched subtype-specific therapies for AML patients.
A new editorial in Gut explores how AI-powered radiomic analysis could identify occult pancreatic cancer missed by standard imaging.
The landmark NordICC trial's 13-year data shows one colonoscopy meaningfully reduces cancer incidence but doesn't significantly lower mortality.
Researchers discover a BBB-like vascular shield in small cell lung cancer that blocks immune cells — and find a drug combo to overcome it.
Long-elusive cancer-driving proteins are yielding to innovative drug strategies, opening new frontiers in oncology treatment.
